



2nd SCI/RSC Symposium on Antimicrobial Drug Discovery

Monday 12 - Tuesday 13 November 2018
SCI, London, UK



Organised by SCI's Fine Chemicals Group &
RSC's Biological and Medicinal Chemistry Sector



Synopsis

Rising antimicrobial resistance is decreasing the efficacy of existing treatments for infection. With the alarming prospect of a post-antibiotic era, it is vital that we refresh the drug pipeline with new therapies and therapeutics that act through novel modes of action. With pressure from governments and increased public awareness of this growing problem, renewed interest from industry and academia has led to a resurgence in antimicrobial drug discovery, with the exciting prospect of new and innovative technologies and approaches for combating infection.

Following the first successful event in 2016, this meeting will examine the current state of the art in antimicrobial drug discovery from a medicinal chemist's perspective. Coinciding with World Antibiotics Awareness week, a two-day programme of speakers from industry and academia will highlight the challenges associated with discovering and developing new antimicrobials, whilst also showcasing emerging strategies that are being developed to tackle infection.

Attendees

Bringing together leading exponents in the field from industry and academia, the meeting will appeal to anyone with an interest in antimicrobial drug discovery. With great opportunities for academic-industrial partnerships, researchers from both sectors will also benefit from the networking opportunities that the meeting will provide.

Programme

Monday 12 November

- 12:00** Registration, exhibition and lunch
- 13:00** Opening remarks
- 13:10** **Antibiotics: challenges and opportunities**
Dr Stephen Baker, GlaxoSmithKline
- 13:55** **Rational and irrational discovery of novel interventions to treat drug-resistant infections**
Prof Matt Cooper, University of Queensland and Inflazome
- 14:40** **Flash poster presentations**
- 15:00** Refreshment break and exhibition
- 15:30** **Towards photopharmacological antimicrobial chemotherapy**
Dr Matthew Fuchter, Imperial College London
- 16:00** **SPARKing new antibiotic discovery**
Wes Kim, The Pew Charitable Trusts
- 16:30** **Research and development of new antimicrobial drugs and combinations: a not-for-profit approach**
Prof Laura Piddock, Global Antibiotic Research & Development Partnership
- 17:15** Networking and refreshments



#AntibioticGap

Tuesday 13 November

- 09:00 Rules for bacterial penetration - what we know and what we don't**
Dr Paul Finn, Oxford Drug Design
- 09:30 Reversing efflux-mediated resistance to reinvent broad-spectrum antibiotics**
Dr K Miraz Rahman, King's College London
- 10:00 Predictive guidelines for compound accumulation lead to new broad-spectrum antibiotics**
Prof Paul Hergenrother, University of Illinois
- 10:45** Refreshment break and exhibition
- 11:15 Non-hydroxamate LpxC inhibitors**
Dr Alastair Parkes, Evotec
- 11:45 Novel immunotherapeutics to target Gram-negative bacterial infections**
Dr Emma Leire, Centauri Therapeutics
- 12:15 Analysis of potassium (K+) efflux systems (Kef) as an antibiotic target in pathogenic bacteria**
Catherine Haslam, University of Oxford
- 12:30 Turning strength into a weakness: exploiting resistance as a novel therapeutic target**
Lindsay Evans, Imperial College London
- 12:45 MAPS: Multiparameter Assay for Profiling Susceptibility**
Lisa Miller, University of York
- 13:00** Lunch and exhibition
- 14:00 Short antimicrobial peptides - their potential against multidrug-resistant bacteria**
Dr Kai Hilpert, St George's, University of London
- 14:30 From HTS to preclinical candidate: a novel small-molecule antibiotic for the treatment of drug-resistant *Neisseria gonorrhoeae***
Dr Paul Meo, Summit Therapeutics
- 15:00** Refreshment break and exhibition
- 15:30 Metallo β -lactamase inhibitors: an approach to combat the threat of emerging carbapenem resistance due to metallo β -lactamase enzymes in Gram-negative bacteria**
Dr David Davies, AntaBio
- 16:00 Challenges in antibacterial drug discovery**
Prof Ian Gilbert, University of Dundee
- 16:45** Closing remarks

Registration Fees

Before 5 October 2018

SCI/RSC Member	£150
SCI/RSC Student	£50
SCI/RSC Subsidised Member	£100
Non-member	£200

After 5 October 2018

SCI/RSC Member	£180
SCI/RSC Student	£60
SCI/RSC Subsidised Member	£120
Non-member	£240

Register online at: www.soci.org/events

Partner

Sponsor



Venue

SCI
14/15 Belgrave Square
London
SW1X 8PS



#AntibioticGap

Exhibition and Sponsorship

An exhibition will take place alongside the conference. Companies and organisations who may wish to exhibit, please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.

For information on travel and the most up-to-date speaker programme, please visit <http://bit.ly/AMR2018>

About SCI

SCI is a forward-looking multidisciplinary membership organisation connecting industry, government and academia to advance the application of science for the benefit of society.

SCI offers a network of contacts spanning the chemical and chemical-using industries, together with a rolling programme of conferences, events and prestigious awards which help further knowledge and support those involved in the sector, no matter what stage they're at in their careers.

SCI is the publisher of many well respected peer-reviewed journals and industry leader Chemistry & Industry magazine (C&I).

Join SCI today to network with people across the chemical and chemical-using industries and make connections that spark innovation, get careers moving, and set business ideas rolling. Visit www.soci.org/membership to find out more and join us.

